P53 codon 72 Arg/Pro polymorphism and glioma risk: An updated meta-analysis

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 3121-3130

  He, Fang ^a   Xia, Yi ^a   Liu, Huafeng ^a   Li, Jin ^b   Wang, Chao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b PLA   (China)

Author keywords

Glioma; Meta analysis; P53; Polymorphism

Indexed keywords

EID: 84885429765     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0880-2     Document Type: Article

References (42)

1. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001;17:503-11.
2. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205:613-21.
3. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93-108.
4. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009;472:323-42.
5. Backes DM, Siddiq A, Cox DG, Calboli FC, Gaziano JM, Ma J, et al. Single-nucleotide polymorphisms of allergy-related genes and risk of adult glioma. J Neurooncol. 2013.
6. Wang D, Hu Y, Gong H, Li J, Ren Y, Li G, et al. Genetic polymorphisms in the DNA repair gene XRCC1 and susceptibility to glioma in a Han population in northeastern China: a case-control study. Gene. 2012;509:223-7.
7. Hou WG, Ai WB, Bai XG, Dong HL, Li Z, Zhang YQ, et al. Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population. PLoS One. 2012;7:e37531.
8. Fan Y, Lee TV, Xu D, Chen Z, Lamblin AF, Steller H, et al. Dual roles of Drosophila p53 in cell death and cell differentiation. Cell Death Differ. 2010;17:912-21.
9. Alsafadi S, Tourpin S, Andre F, Vassal G, Ahomadegbe JC. P53 family: at the crossroads in cancer therapy. Curr Med Chem. 2009;16:4328-44.
10. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442-55.
11. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011;2011:978312.
12. Kim SH, Dass CR. p53-targeted cancer pharmacotherapy: move towards small molecule compounds. J Pharm Pharmacol. 2011;63:603-10.
13. Olsson H, Hultman P, Rosell J, Soderkvist P, Jahnson S. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urol. 2013;13:5.
14. Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, et al. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma. DNA Cell Biol. 2013;32:19-27.
15. Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, et al. p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012;18:6407-15.
16. Sakurai N, Iwamoto S, Miura Y, Nakamura T, Matsumine A, Nishioka J, et al. Novel p53 splicing site mutation in Li-Fraumeni-like syndrome with osteosarcoma. Pediatr Int. 2013;55:107-11.
17. Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64:5560-3.
18. Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res. 2005;137:98-103.
19. Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Criniere E, et al. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet. 2007;177:103-7.
20. Malmer BS, Feychting M, Lonn S, Lindstrom S, Gronberg H, Ahlbom A, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82:229-37.
21. Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16:1655-61.
22. Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, et al. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet. 2008;180:14-9.
23. Pinto GR, Yoshioka FK, Silva RL, Clara CA, Santos MJ, Almeida JR, et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res. 2008;7:207-16.
24. El Hallani S, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, et al. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology. 2009;72:332-6.
25. Jha P, Pathak P, Chosdol K, Suri V, Sharma MC, Kumar G, et al. TP53 polymorphisms in gliomas from Indian patients: study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp Mol Pathol. 2011;90:167-72.
26. Jin T, Zhang J, Li G, Li S, Yang B, Chen C, et al. TP53 and RPA3 gene variations were associated with risk of glioma in a Chinese Han population. Cancer Biother Radiopharm. 2013;28:248-53.
27. Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256-66.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
30. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
32. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 70-1.
33. Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP, James CD. Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics. 2001;3:159-62.
34. Hayes VM, Dirven CM, Dam A, Verlind E, Molenaar WM, Mooij JJ, et al. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol. 1999;9:463-7.
35. Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Criniere E, et al. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 2008;1198:16-20.
36. Patt S, Gries H, Giraldo M, Cervos-Navarro J, Martin H, Janisch W, et al. p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum Pathol. 1996;27:586-9.
37. Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol. 2009;19:188-94.
38. Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ, Xie LP. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol. 2013;11:22.
39. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003;169:1219-28.
40. Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep. 2003;10:711-4.
41. Kara N, Karakus N, Ulusoy AN, Ozaslan C, Gungor B, Bagci H. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 2010;29:387-92.
42. Shi M, Huang R, Pei C, Jia X, Jiang C, Ren H. TP53 codon 72 polymorphism and glioma risk: a meta-analysis. Oncol Lett. 2012;3:599-606.